Eclipse Diagnostics, the newly formed subsidiary of Large Scale Biology, has gotten its management team in place. Comprised entirely of members of the parent company, which will continue to focus on biomolecule production, the group will be responsible for commercializing the biomarker amplification filter technology — known as BAMF — that serves as the foundation of the new company.
John Rakitan, senior vice president and general manager for Eclipse, says the technology is designed to screen thousands of potential markers to find a clearer diagnostic signature than any one marker might offer. “This concept is not new,” he says, but the company is clearly committed to it: “This is going to be a method that we think will actually revolutionize medicine.”
Kevin Ryan, president and CEO of Large Scale Biology, is the new president of Eclipse. He’s joined by Rakitan, Gary Wolfe as CSO, Guy della Cioppa as senior veep of business development, and Ronald Artale in the position of CFO. John Chute, a Duke Medical Center faculty member who used to work for LSBC, has signed on as Eclipse’s first scientific advisor.
The team will start with a focus on ovarian cancer, which they’ve already been pursuing thanks to a collaboration with Lance Liotta and Emanuel Petricoin at the NCI/FDA Clinical Proteomics Program. In the future, Rakitan says, Eclipse will likely look into other cancers, such as lung, breast, pancreatic, and possibly more ovarian datasets. If the BAMF technology works as well as the Eclipse team is betting it will, Rakitan says, “It’s going to provide better patient outcome and dramatically reduce the cost of healthcare.”
— Meredith Salisbury